[1] Walkington, L. and Coleman, R.E. (2011) Advances in Management of Bone Disease in Breast Cancer. Bone, 48, 80-87.
https://doi.org/10.1016/j.bone.2010.05.037
[2] Grávalos, C., Rodríguez, C., Sabino, A., et al. (2016) SEOM Clinical Guideline for Bone Metastases from Solid Tumours. Clinical and Translational Oncology, 18, 1243-1253.
https://doi.org/10.1007/s12094-016-1590-1
[3] Arch, V. (2017) Breast Carcinoma Subtypes Show Different Patterns of Metastatic Behavior. Virchows Archiv, 470, 275-283.
https://doi.org/10.1007/s00428-017-2065-7
[4] Cerner Multum, Inc. (2017) Version: 15.02.
https://www.drugs.com/pro/zometa.html
[5] Tanaka, R., Yonemori, K., Hirakawa, A., et al. (2016) Risk Factors for Developing Skeletal-Related Events in Breast Cancer Patients with Bone Metastases Undergoing Treatment with Bone-Modifying Agents. Oncologist, 21, 508-513.
https://doi.org/10.1634/theoncologist.2015-0377
[6] Kohno, N., Aogi, K., Minami, H., et al. (2005) Zoledronic Acid Significantly Reduces Skeletal Complications Compared with Placebo in Japanese Women with Bone Metastases from Breast Cancer: A Randomized, Placebo-Controlled Trial. Journal of Clinical Oncology, 23, 14-21.
https://doi.org/10.1200/JCO.2005.05.116
[7] Early Breast Cancer Trialists’ Collaborative Group, Coleman, R., Powles, T., Paterson, A., et al. (2015) Adjuvant Bisphosphonate Treatment in Early Breast Cancer: Meta-Analyses of Individual Patient Data from Randomised Trials. Lancet, 386, 1353-1361.
https://doi.org/10.1016/S0140-6736(15)60908-4
[8] Liede, A., Jerzak, K.J., Hernandez, R.K., et al. (2016) The Incidence of Bone Metastasis after Early-Stage Breast Cancer in Canada. Breast Cancer Research and Treatment, 156, 587-595.
https://doi.org/10.1007/s10549-016-3782-3
[9] Irawan, C., Atmakusumah, D., Siregar, N.C., et al. (2016) Expression of Biomarkers CXCR4, IL11-RA, TFF1, MLF1P in Advanced Breast Cancer Patients with Bone Metastatic: a Diagnostic Study. Acta Medica Indonesiana, 48, 261-268.
[10] Chiu, J.H., Wen, C.S., Wang, J.Y., et al. (2017) Role of Estrogen Receptors and Src Signaling in Mechanisms of Bone Metastasis by Estrogen Receptor Positive Breast Cancers. Journal of Translational Medicine, 15, 97.
https://doi.org/10.1186/s12967-017-1192-x
[11] Koizumi, M., Yoshimoto, M., Kasumi, F., et al. (2003) Comparison between Solitary and Multiple Skeletal Metastatic Lesions of Breast Cancer Patients. Annals of Oncology, 14, 1234-1240.
https://doi.org/10.1093/annonc/mdg348
[12] Lee, S.J., Park, S., Ahn, H.K., et al. (2011) Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast Cancer. Cancer Research and Treatment, 43, 89-95.
https://doi.org/10.4143/crt.2011.43.2.89
[13] Sciubba, D.M., Gokaslan, Z.L., Suk, I., et al. (2007) Positive and Negative Prognostic Variables for Patients Undergoing Spine Surgery for Metastatic Breast Disease. European Spine Journal, 16, 1659-1667.
https://doi.org/10.1007/s00586-007-0380-4